Innovative uses of tumor necrosis factor α inhibitors

Dermatologic Clinics

Volumn 28, Issue 3, 2010, Pages 559-575

  Mazza, Joni ^a,b   Rossi, Anthony ^a   Weinberg, Jeffrey M ^a,c  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Adalimumab; Biologic; Etanrcept; Infliximab; Off label; Skin

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CALCIPOTRIOL; CELL ADHESION MOLECULE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DAPSONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; ETRETIN; HYDROCORTISONE; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; ISOTRETINOIN; METHOTREXATE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE GRAFT VERSUS HOST DISEASE; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; BEHCET DISEASE; BULLOUS PEMPHIGOID; CHILL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE RELEASE; DERMATOMYOSITIS; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA ANNULARE CENTRIFUGUM; GENETIC POLYMORPHISM; GRANULOMA ANNULARE; HAILEY HAILEY DISEASE; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOSTIMULATION; INFLAMMATION; INJECTION SITE REACTION; LOADING DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; MYCOBACTERIOSIS; NECROBIOSIS LIPOIDICA; OFF LABEL DRUG USE; OPPENHEIM URBACH SYNDROME; OPPORTUNISTIC INFECTION; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PYODERMA GANGRENOSUM; RETICULOHISTIOCYTOSIS; REVIEW; RHEUMATOID ARTHRITIS; SAPHO SYNDROME; SARCOIDOSIS; SCLERODERMA; SIDE EFFECT; SPLIT THICKNESS SKIN GRAFT; SUBCORNEAL PUSTULAR DERMATOSIS; SUPPURATIVE HIDRADENITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; TOXIC EPIDERMAL NECROLYSIS; ULCERATIVE COLITIS; ULTRAVIOLET B RADIATION; UNITED STATES; UPREGULATION; URTICARIA; VASCULITIS;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; OFF-LABEL USE; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN DISEASES; THERAPIES, INVESTIGATIONAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953247287     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.03.009     Document Type: Review

References (136)

1. Kupper T.S. Immunologic targets in psoriasis. N Engl J Med 2003, 349(21):1987-1990.
2. Robert C., Kupper T.S. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999, 341(24):1817-1828.
3. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003, 10(1):45-65.
4. Gisondi P., Gubinelli E., Cocuroccia B., et al. Targeting tumor necrosis factor-alpha in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004, 3(2):175-183.
5. Chaudhari U., Romano P., Mulcahy L.D., et al. Efficacy and safety of infliximab monotherapy for plaque type psoriasis: a randomized trial. Lancet 2001, 357:1842-1846.
6. Behnam S.M., Behnam S.E., Koo J.Y. TNF-alpha inhibitors and congestive heart failure. Skinmed 2005, 4:363-368.
7. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
8. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
9. Mohan N., Edwards E.T., Cupps T.R., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
10. Kary S., Worm M., Audring H., et al. New onset or exacerbation of psoratic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 2006, 65:405-407.
11. Yamauchi P.S., Gindi V., Lowe N.J. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin 2004, 22:449-459. ix.
12. Khanna D., McMahon M., Furst D.E. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004, 27(5):307-324.
13. Mohler K.M., Torrance D.S., Smith C.A., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993, 151:1548-1561.
14. Bathon J.M., Martin R.W., Fleischmann R.M., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
15. Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
16. Salmon J.E., Alpert D. Are we coming to terms with tumor necrosis factor inhibition in pregnancy?. Arthritis Rheum 2006, 54:2353-2355.
17. Mease P.J. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther 2005, 5:1491-1504.
18. Keystone E., Haraoui B. Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am 2004, 30:349-364. vii.
19. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies; systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
20. Deng A., Harvey V., Sina B., et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 2006, 142:198-202.
21. Roberts S.D., Wilkes D.S., Burgett R.A., et al. Refractory sarcoidosis responding to infliximab. Chest 2003, 124:2028-2031.
22. Meyerle J.H., Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol 2003, 2:413-414.
23. Utz J.P., Limper A.H., Kalra S., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124:177-185.
24. Khanna D., Liebling M.R., Louie J.S. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003, 30:1864-1867.
25. Philips M.A., Lynch J., Azmi F.H. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol 2005, 53:917.
26. Heffernan M.P., Smith D.I. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006, 142:17-19.
27. Adams B.B. Colocalization of granuloma annulare and mid-dermal elastolysis. J Am Acad Dermatol 2003, 48:S25.
28. Hertl M.S., Haendle I., Schuler G., et al. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab. Br J Dermatol 2005, 152:552-555.
29. Shupack J., Siu K. Resolving granuloma annulare with etanercept. Arch Dermatol 2006, 142:394-395.
30. Lowitt M.H., Dover J.S. Necrobiosis lipoidica. J Am Acad Dermatol 1991, 25:735.
31. Ullman S., Dahl M.V. Necrobiosis lipoidica. An immunofluorescence study. Arch Dermatol 1977, 113:1671-1673.
32. Cummins D.L., Hiatt K.M., Mimouni D., et al. Generalized necrobiosis lipoidica treated with a combination of split-thickness autografting and immunomodulatory therapy. Int J Dermatol 2004, 43:852-854.
33. Zeichner J.A., Stern D.W., Lebwohl M. Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006, 54(Suppl):S120-S121.
34. Kolde G., Muche J.M., Schulze P., et al. Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica. Dermatology 2003, 206:180-181.
35. Wolff K., Stingl G. Pyoderma gangrenosum. Fitzpatrick's dermatology in general medicine. 5th edition 1999, 1140-1148. McGraw-Hill Health Professions Division, New York. I.M. Freedberg, A.Z. Eisen, K. Wolff (Eds.).
36. Crowson A.N., Mihm M.C., Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003, 30:97.
37. Regueiro M., Valentine J., Plevy S., et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003, 98(8):1821-1826.
38. Ljung T., Staun M., Grove O., et al. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002, 37:1108-1110.
39. Arnott I.D., McDonald D., Williams A., et al. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 2001, 15:1639-1646.
40. Kaufman I., Caspi D., Yeshurun D., et al. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 2005, 25(6):406-410.
41. McGowan J.W., Johnson C.A., Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 2004, 3:441-444.
42. Hubbard V.G., Friedmann A.C., Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 2005, 152:1059-1061.
43. Goldenberg G., Jorizzo J.L. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatolog Treat 2005, 16:347-349.
44. Pastor N., Betlloch I., Pascual J.C., et al. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin Exp Dermatol 2006, 31:152-153.
45. Yamauchi P.S., Turner L., Lowe N.J., et al. Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006, 54(Suppl):S122-S126.
46. Grob J.J., Mege J.L., Capo C., et al. Role of tumor necrosis factor-alpha in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo. J Am Acad Dermatol 1991, 25:944-947.
47. Voigtlander C., Luftl M., Schuler G., et al. Infliximab (antitumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001, 137:1571-1574.
48. Bartolucci P., Ramanoelina J., Cohen P., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study in 10 patients. Rheumatology (Oxford) 2002, 41:1126-1132.
49. Booth A., Harper L., Hammad T., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004, 15:717-721.
50. Booth A.D., Jefferson H.J., Ayliffe W., et al. Safety and efficacy of TNF-alpha blockade in relapsing vasculitis. Ann Rheum Dis 2002, 61:559.
51. Gause A., Arbach O., Reinhold-Keller E., et al. Induction of remission with infliximab in active generalized Wegener's granulomatosis is effective but complicated by serious infection. Arthritis Rheum 2003, 48:s208. [abstract].
52. Lamprecht P., Voswinkel J., Lilienthal T., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002, 41:1303-1307.
53. Josselin L., Mahr A., Cohen P., et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008, 67(9):1343-1346.
54. Keystone E.C. The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis 2004, 63(Suppl 2):ii79-ii83. 189.
55. Stone J.H., Uhlfelder M.L., Hellmann D.B., et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001, 44:1149-1154.
56. D'Auria L., Cordiali Fei P., Ameglio F. Cytokines and bullous pemphigoid. Eur Cytokine Netw 1999, 10:123-134.
57. D'Auria L., Mussi A., Bonifati C., et al. Increased serum IL-6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid: relationships with disease activity. J Eur Acad Dermatol Venereol 1999, 12:11-15.
58. Giacalone B., D'Auria L., Bonifati C., et al. Decreased interleukin-7 and transforming growth factor-beta1 levels in blister fluids as compared to the respective serum levels in patients with bullous pemphigoid. Opposite behavior of TNF-alpha, interleukin-4 and interleukin-10. Exp Dermatol 1998, 7:157-161.
59. Rhodes L.E., Hashim I.A., McLaughlin P.J., et al. Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol 1999, 79:288-290.
60. Lee S.J., Li Z., Sherman B., et al. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 1993, 34:3522-3525.
61. Yamauchi P.S., Lowe N.J., Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006, 54(Suppl):S121-S122.
62. Sacher C., Rubbert A., Konig C., et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002, 46:113-115.
63. Canizares M.J., Smith D.I., Conners M.S., et al. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol 2006, 142:1457-1461.
64. Aringer M., Smolen J.S. TNF inhibition in SLE: where do we stand?. Lupus 2009, 18(1):5-8.
65. Levälampi T., Korpela M., Vuolteenaho K., et al. Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. Rheumatol Int 2008, 28(3):261-269.
66. Aringer M., Graninger W.B., Steiner G., et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004, 50:3161-3169. 9-16.
67. Fautrel B., Foltz V., Frances C., et al. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum 2002, 46:1408-1409. [author reply: 1409].
68. Norman R., Greenberg R.G., Jackson J.M. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006, 54(Suppl):S139-S142.
69. Aringer M., Houssiau F., Gordon C., et al. Adverse events and efficacy of TNF-{alpha} blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009, 48(11):1451-1454.
70. Uppal S.S., Hayat S.J., Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009, 18(8):690-697.
71. Costa M.F., Said N.R., Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008, 37(6):381-387.
72. Shi-Wen X., Panesar M., Vancheeswaran R., et al. Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen. Arthritis Rheum 1994, 37(11):1689-1697.
73. Koca S.S., Isik A., Ozercan I.H., et al. Effectiveness of etanercept in bleomycin-induced experimental scleroderma. Rheumatology (Oxford) 2008, 47(2):172-175.
74. Ellman M.H., MacDonald P.A., Hayes F.A. Etanercept as a treatment for diffuse scleroderma: a pilot study. Arthritis Rheum 2000, 43:s392.
75. Lam G.K., Hummers L.K., Woods A., et al. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007, 34(7):1636-1637.
76. Denton C.P., Engelhart M., Tvede N., et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009, 68(9):1433-1439.
77. Bargagli E., Galeazzi M., Bellisai F., et al. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008, 75(3):346-349.
78. Christopher-Stine L., Wigley F. Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. J Rheumatol 2003, 30:2725-2727.
79. Menon Y., Cucurull E., Espinoza L.R. Pancytopenia in a patient with scleroderma treated with infliximab. Rheumatology (Oxford) 2003, 42:1273-1274. [author reply: 1274].
80. Efthimiou P., Schwartzman S., Kagen L.J. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006, 65(9):1233-1236.
81. Riley P., McCann L.J., Maillard S.M., et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008, 47(6):877-880.
82. Hengstman G.J., De Bleecker J.L., Feist E., et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008, 59(3-4):159-163.
83. Dold S., Justiniano M.E., Marquez J., et al. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 2007, 26:1186-1188.
84. Roddy E., Courtney P.A., Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford) 2002, 41:1194-1195.
85. Goossens P.H., Verburg R.J., Breedveld F.C. Remission of Behcet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 2001, 60:637.
86. Olivieri I., Padula A., Leccese P., et al. Long-lasting remission of severe Behçet's disease after the end of infliximab therapy. J Rheumatol 2009, 36(4):855.
87. Jalili A., Kinaciyan T., Barisani T., et al. Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab. Iran J Immunol 2009, 6(1):55-58.
88. Yamada Y., Sugita S., Tanaka H., et al. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behcet's disease. Br J Ophthalmol 2010, 94(3):284-288.
89. Iwata S., Saito K., Yamaoka K., et al. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease. Rheumatology (Oxford) 2009, 48(8):1012-1013.
90. Melikoglu M., Kural-Seyahi E., Tascilar K., et al. The unique features of vasculitis in Behçet's syndrome. Clin Rev Allergy Immunol 2008, 35(1-2):40-46.
91. Belzunegui J., López L., Paniagua I., et al. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease. Clin Exp Rheumatol 2008, 26(4 Suppl 50):S133-S134.
92. Ariyachaipanich A., Berkelhammer C., Nicola H. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis 2009, 15(12):1769-1771.
93. Yildiz N., Alkan H., Ardic F., et al. Successful treatment with adalimumab in a patient with coexisting Behçet's disease and ankylosing spondylitis. Rheumatol Int 2009, [Epub ahead of print].
94. Takase K., Ohno S., Ideguchi H., et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int 2009, [Epub ahead of print].
95. Estrach C., Mpofu S., Moots R.J. Behcet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 2002, 41:1213-1214.
96. Yucel A.E., Kart-Koseoglu H., Akova Y.A., et al. Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behcet's disease. Rheumatology (Oxford) 2004, 43:394-396.
97. Cooke K.R., Hill G.R., Gerbitz A., et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000, 70:272-279.
98. Hattori K., Hirano T., Miyajima H., et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998, 91:4051-4055.
99. Schmaltz C., Alpdogan O., Muriglan S.J., et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2003, 101:2440-2445.
100. Tsukada N., Kobata T., Aizawa Y., et al. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999, 93:2738-2747.
101. Holler E., Kolb H.J., Moller A., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990, 75:1011-1016.
102. Couriel D., Hicks K., Ipolotti C. Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: an update. Blood 2000, 96:400a.
103. Jacobsohn D.A., Hallick J., Anders V., et al. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003, 74:119-124.
104. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004, 104:649-654.
105. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004, 89:1352-1359.
106. Srinivasan R., Chakrabarti S., Walsh T. Improved survival in steroid refractory acute graft versus host disease after nonmyeloablative allogeneic transplantation using daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124:777-786.
107. Rao K., Rao A., Karlsson H., et al. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. J Pediatr Hematol Oncol 2009, 31(6):456-461.
108. Antin J.H., Chen A.R., Couriel D.R., et al. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2004, 10:655-668.
109. Uberti J.P., Ayash L., Ratanatharathorn V., et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:680-687.
110. Chiang K.Y., Abhyankar S., Bridges K., et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002, 73:665-667.
111. Marty F.M., Lee S.J., Fahey M.M., et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003, 102:2768-2776.
112. Drosou A., Kirsner R.S., Welsh E., et al. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003, 7:382-386.
113. Barth D., Harth W., Treudler R., et al. Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate. J Dtsch Dermatol Ges 2009, 7(12):1071-1073.
114. Müller H., Gattringer C., Zelger B., et al. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol 2008, 59(Suppl 5):S65-S70.
115. Davis K.F., Wu J.J., Murase J.E., et al. Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy. Arch Dermatol 2007, 143(12):1597-1599.
116. Seckin D., Tula E., Ergun T. Successful use of etanercept in type I pityriasis rubra pilaris. Br J Dermatol 2008, 158(3):642-644.
117. Cox V., Lesesky E.B., Garcia B.D., et al. Treatment of juvenile pityriasis rubra pilaris with etanercept. J Am Acad Dermatol 2008, 59(5 Suppl):S113-S114.
118. Walling H.W., Swick B.L. Pityriasis rubra pilaris responding rapidly to adalimumab. Arch Dermatol 2009, 145(1):99-101.
119. Wagner A.D., Andresen J., Jendro M.C., et al. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002, 46:1965-1968.
120. Olivieri I., Padula A., Ciancio G., et al. Persistent efficacy of tumor necrosis factor alpha blockage therapy in SAPHO syndrome: comment on the article by Wagner et al. Arthritis Rheum 2003, 48(5):1467. [author reply: 1468].
121. Moll C., Hernández M.V., Cañete J.D., et al. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin Arthritis Rheum 2008, 37(5):299-306.
122. Kovach B.T., Calamia K.T., Walsh J.S., et al. Treatment of multicentric reticulohistiocytosis with etanercept. Arch Dermatol 2004, 140:919-921.
123. Matejicka C., Morgan G.J., Schlegelmilch J.G. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum 2003, 48:864-866.
124. Lee M.W., Lee E.Y., Jeong Y.I., et al. Successful treatment of multicentric reticulohistiocytosis with a combination of infliximab, prednisolone and methotrexate. Acta Derm Venereol 2004, 84:478-479.
125. Shannon S.E., Schumacher H.R., Self S., et al. Multicentric reticulohistiocytosis responding to tumor necrosis factor-alpha inhibition in a renal transplant patient. J Rheumatol 2005, 32:565-567.
126. Sellam J., Deslandre C.J., Dubreuil F., et al. Refractory multicentric reticulohistiocytosis treated by infliximab: two cases. Clin Exp Rheumatol 2005, 23:97-99.
127. Kalajian A.H., Callen J.P. Multicentric reticulohistiocytosis successfully treated with infliximab: an illustrative case and evaluation of cytokine expression supporting anti-tumor necrosis factor therapy. Arch Dermatol 2008, 144:1360-1366.
128. Correia O., Delgado L., Barbosa I.L., et al. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002, 47:58-62.
129. Paquet P., Nikkels A., Arrese J.E., et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 1994, 130(5):605-608.
130. Paquet P., Pierard G.E. Soluble fractions of tumor necrosis factor-alpha, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns. Int J Mol Med 1998, 1:459-462.
131. Paquet P., Paquet F., Al Saleh W., et al. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol 2000, 22:413-417.
132. Paul C., Wolkenstein P., Adle H., et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996, 134:710-714.
133. Fischer M., Fiedler E., Marsch W.C., et al. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002, 146:707-709.
134. Famularo G., Di Dona B., Canzona F., et al. Etanercept for toxic epidermal necrolysis. Ann Pharmacother 2007, 41:1083-1084.
135. Gubinelli E., Canzona F., Tonanzi T., et al. Case report: toxic epidermal necrolysis successfully treated with etanercept. J Dermatol 2009, 36:150-153.
136. Minni J., Sarro R. A novel therapeutic approach to erythema annulare centrifugum. J Am Acad Dermatol 2006, 54(Suppl):S134-S135. 138:916-22.